Cardiff Oncology, Inc. (CRDF) - Dilution Analysis

10-Q filing | 68.4M shares outstanding

8-K filing: Cardiff Oncology, Inc. appointed Josh Muntner as Chief Financial Officer, Ajay Aggarwal, MD, MBA as Chief Operating Officer, and Mani Mohindru, Ph.D. as President and Chief Executive Officer.

10-Q filing | 66.9M shares outstanding

8-K filing: Cardiff Oncology, Inc. announced the appointment of Dr. Roger Sidhu as its new Chief Medical Officer, granting him a non-qualified option to purchase 600,000 shares of common stock at an exercise price of $3.86 per share as an inducement grant.

S-3/A filing: This S-3/A filing contains a base prospectus which covers the offering, issuance and sale by the company of up to $400 million in the aggregate of securities, and a sales agreement prospectus covering the offering, issuance and sale by the company of up to a maximum aggregate offering price of $150 million of common stock under an Open Market Sale Agreement with Jefferies LLC.

10-Q filing | 66.5M shares outstanding

S-3 filing: The registration statement covers the offering, issuance and sale of up to $400 million in the aggregate of securities and up to a maximum aggregate offering price of $150 million of common stock under an Open Market Sale Agreement with Jefferies LLC.

10-K filing | 66.5M shares outstanding

8-K filing: Cardiff Oncology, Inc. entered into an underwriting agreement to sell 15,384,619 shares of its common stock at $2.60 per share, expecting to receive gross proceeds of approximately $40 million before deductions. ($40.0M proceeds)

10-Q filing | 46.9M shares outstanding

10-Q filing | 44.8M shares outstanding

8-K filing: The Board of Directors of Cardiff Oncology, Inc. amended the Company's By-laws to conform to public disclosures about voting standards and approved the rescinding and granting of stock options.

10-Q filing | 44.7M shares outstanding

10-K filing | 44.7M shares outstanding

10-Q filing | 44.7M shares outstanding

10-Q filing | 44.7M shares outstanding

8-K filing: Cardiff Oncology, Inc. granted non-qualified stock option awards to purchase an aggregate of 50,016 shares of its common stock to one new employee on July 24, 2023.

8-K filing: On June 20, 2023, Cardiff Oncology, Inc. granted non-qualified stock option awards to purchase an aggregate of 40,032 shares of its common stock to one new employee.

10-Q filing | 44.7M shares outstanding

10-K filing | 43.6M shares outstanding

10-Q filing | 43.3M shares outstanding

10-Q filing | 43.3M shares outstanding

10-Q filing | 43.2M shares outstanding

S-3 filing: The company is offering 38,314,176 shares of common stock at a price of $2.61 per share, for aggregate gross proceeds of approximately $100,000,000, to be used for general corporate purposes.

10-K filing | 39.0M shares outstanding

8-K filing: On January 31, 2022, Cardiff Oncology, Inc. granted non-qualified stock option awards to purchase an aggregate of 55,008 shares of its common stock to one new employee.

8-K filing: On December 2, 2021, Cardiff Oncology, Inc. granted non-qualified stock option awards to purchase an aggregate of 200,112 shares of its common stock to two new employees.

8-K filing: Cardiff Oncology, Inc. entered into a Securities Purchase Agreement with Pfizer Inc. for a registered direct offering of 2,411,575 shares of common stock at $6.22 per share, resulting in gross proceeds of approximately $15.0 million before expenses. ($15.0M proceeds)

10-Q filing | 39.6M shares outstanding

10-Q filing | 38.8M shares outstanding

10-Q filing | 37.6M shares outstanding

10-K filing | 37.1M shares outstanding

10-Q filing | 35.3M shares outstanding

10-Q filing | 23.2M shares outstanding

S-1/A filing: The filing relates to a registered offering and private placement of securities, including common stock, warrants, and preferred stock.

S-1 filing: The filing is related to a registered offering and private placement of securities, including common stock, warrants and preferred stock.

S-1 filing: This S-1 filing includes information regarding registered offerings and private placements of securities, including common stock, pre-funded warrants, and warrants, with entities such as Lincoln Park Capital Fund, LLC and POC Capital, LLC, as well as directors and the CEO of the company.

8-K filing: Cardiff Oncology, Inc. issued 602,833 shares of common stock and a warrant exercisable for 859,813 shares of common stock to POC Capital, LLC, and sold 447,761 shares of common stock to one of its directors. ($5.2M proceeds)

10-Q filing | 12.3M shares outstanding

8-K filing: Trovagene, Inc. entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC, to sell 904,970 shares of common stock and Series K pre-funded warrants to purchase up to 255,000 shares of common stock in a registered direct offering, and Series L warrants to purchase up to 1,159,970 shares of common stock in a concurrent private placement, for gross proceeds of approximately $1.084 million. ($1.08M proceeds)

8-K filing: Trovagene, Inc. entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC, for the sale of 800,000 shares of common stock, Series I pre-funded warrants to purchase up to 131,967 shares of common stock, and Series J warrants to purchase up to 931,967 shares of common stock, for aggregate gross proceeds of approximately $1.0 million. ($2.0M proceeds)

10-K filing | 10.2M shares outstanding